Katherine Stueland Sells 2,731 Shares of GeneDx Holdings Corp. (NASDAQ:WGS) Stock

GeneDx Holdings Corp. (NASDAQ:WGS) CEO Katherine Stueland sold 2,731 shares of the company’s stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $94.73, for a total transaction of $258,707.63. Following the sale, the chief executive officer now directly owns 7,752 shares in the company, valued at $734,346.96. This represents a 26.05 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link.

Katherine Stueland also recently made the following trade(s):

• On Wednesday, January 29th, Katherine Stueland sold 1,657 shares of GeneDx stock. The stock was sold at an average price of $78.48, for a total transaction of $130,041.36.
• On Tuesday, January 7th, Katherine Stueland sold 51,420 shares of GeneDx stock. The stock was sold at an average price of $94.48, for a total transaction of $4,858,161.60.
• On Thursday, January 2nd, Katherine Stueland sold 18,006 shares of GeneDx stock. The stock was sold at an average price of $78.18, for a total transaction of $1,407,709.08.
• On Monday, December 16th, Katherine Stueland sold 10,501 shares of GeneDx stock. The stock was sold at an average price of $76.75, for a total transaction of $805,951.75.

GeneDx Price Performance

WGS opened at $92.08 on Thursday. GeneDx Holdings Corp. has a one year low of $7.72 and a one year high of $115.60. The company has a debt-to-equity ratio of 0.25, a current ratio of 2.40 and a quick ratio of 2.27. The company’s 50 day simple moving average is $84.02 and its 200-day simple moving average is $68.85. The stock has a market capitalization of $2.58 billion, a P/E ratio of -46.98 and a beta of 1.90.

GeneDx (NASDAQ:WGS) last announced its quarterly earnings data on Tuesday, February 18th. The company reported $0.70 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.04 by $0.66. GeneDx had a negative net margin of 17.12% and a positive return on equity of 3.33%. The firm had revenue of $95.64 million for the quarter, compared to analysts’ expectations of $82.24 million. Sell-side analysts anticipate that GeneDx Holdings Corp. will post 0.97 earnings per share for the current fiscal year.

Hedge Funds Weigh In On GeneDx

Hedge funds and other institutional investors have recently bought and sold shares of the business. Barclays PLC boosted its stake in GeneDx by 346.3% in the third quarter. Barclays PLC now owns 18,921 shares of the company’s stock valued at $803,000 after acquiring an additional 14,681 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC bought a new position in GeneDx in the third quarter valued at approximately $325,000. Charles Schwab Investment Management Inc. boosted its stake in GeneDx by 304.3% in the third quarter. Charles Schwab Investment Management Inc. now owns 147,034 shares of the company’s stock valued at $6,240,000 after acquiring an additional 110,666 shares during the last quarter. Chartwell Investment Partners LLC bought a new position in GeneDx in the third quarter valued at approximately $1,722,000. Finally, Lisanti Capital Growth LLC bought a new position in GeneDx in the third quarter valued at approximately $1,554,000. 61.72% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several brokerages have weighed in on WGS. TD Cowen upped their price objective on shares of GeneDx from $75.00 to $118.00 and gave the stock a “buy” rating in a research note on Tuesday, January 7th. The Goldman Sachs Group increased their price target on shares of GeneDx from $70.00 to $80.00 and gave the company a “neutral” rating in a research note on Wednesday, February 19th. Three investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $72.33.

About GeneDx

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.